Open AccessBiochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue
Author(s) -
Samuel Joseph Daniels,
Diana Julie Leeming,
Sönke Detlefsen,
Maria Fuglsang Bruun,
Sara Toftegaard Hjuler,
Kim Henriksen,
Peter Hein,
Morten A. Karsdal,
Sarah Brockbank,
Simon Cruwys
Publication year - 2019
Publication title -
biomedicine and pharmacotherapy
Language(s) - English
Resource type - Journals
eISSN - 1950-6007
pISSN - 0753-3322
DOI - 10.1016/j.biopha.2018.12.130
Subject(s) - pioglitazone , steatohepatitis , liraglutide , medicine , endocrinology , fatty liver , agonist , cholesterol , in vivo , peroxisome proliferator activated receptor , diabetes mellitus , type 2 diabetes , receptor , biology , disease , microbiology and biotechnology
Non-alcoholic steatohepatitis (NASH) is a prevalent disease that is highly associated with the metabolic syndrome and type II diabetes. The development of in vivo models that reflect all nuances of the human NASH pathology is essential for drug discovery and development. We aimed to further characterise a dietary induced model of NASH both biochemically and histologically. In addition, we also investigated whether pioglitazone and liraglutide, drugs that have both been investigated as potential NASH treatments, could modulate the pathological changes induced by the NASH diet. Furthermore, to aid the translation of data from pre-clinical in vivo models, we aimed to adapt the NASH Clinical Research Network (CRN) histological score system for use in rodent studies.